HomeCompareABBV vs NOW

ABBV vs NOW: Dividend Comparison 2026

ABBV yields 3.12% · NOW yields 1.91%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $82.2K in total portfolio value
10 years
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →
NOW
NOW
● Live price
1.91%
Share price
$104.97
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.5K
Annual income
$215.52
Full NOW calculator →

Portfolio growth — ABBV vs NOW

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABBVNOW
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABBV + NOW cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABBV pays
NOW pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
NOW
Annual income on $10K today (after 15% tax)
$161.95/yr
After 10yr DRIP, annual income (after tax)
$183.19/yr
At 15% tax rate, ABBV beats the other by $21,683.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABBV + NOW for your $10,000?

ABBV: 50%NOW: 50%
100% NOW50/50100% ABBV
Portfolio after 10yr
$63.6K
Annual income
$12,970.62/yr
Blended yield
20.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NOW right now

ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
NOW
Analyst Ratings
58
Buy
8
Hold
1
Sell
Consensus: Buy
Price Target
$196.29
+87.0% upside vs current
Range: $115.00 — $263.00
Altman Z
6.1
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABBV buys
7
NOW buys
14
PoliticianChamberTickerTypeAmountDate
Charles J. "Chuck" Fleischmann🏢 House$NOW▲ Buy$1,001 - $15,0002026-02-20
Byron Donalds🏢 House$NOW▲ Buy$1,001 - $15,0002026-02-10
Byron Donalds🏢 House$NOW▲ Buy$1,001 - $15,0002026-02-10
Tony Wied🏢 House$NOW▲ Buy$15,001 - $50,0002026-02-04
Josh Gottheimer🏢 House$NOW▼ Sell$1,001 - $15,0002026-01-30
Markwayne Mullin🏛 Senate$NOW▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$NOW▲ Buy$15,001 - $50,0002025-12-29
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Josh Gottheimer🏢 House$NOW▼ Sell$1,001 - $15,0002025-12-17
Julie Johnson🏢 House$NOW▼ Sell$1,001 - $15,0002025-12-09
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABBVNOW
Forward yield3.12%1.91%
Annual dividend / share$6.65$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR40.6%0%
Portfolio after 10y$104.7K$22.5K
Annual income after 10y$25,725.73$215.52
Total dividends collected$63.0K$2.0K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy
Analyst price target$256.15$196.29

Year-by-year: ABBV vs NOW ($10,000, DRIP)

YearABBV PortfolioABBV Income/yrNOW PortfolioNOW Income/yrGap
1← crossover$11,559$438.51$10,891$190.53+$668.00ABBV
2$13,494$640.86$11,847$193.92+$1.6KABBV
3$15,951$945.97$12,873$197.15+$3.1KABBV
4$19,152$1,413.89$13,975$200.22+$5.2KABBV
5$23,443$2,146.38$15,156$203.13+$8.3KABBV
6$29,391$3,321.96$16,423$205.89+$13.0KABBV
7$37,948$5,265.87$17,781$208.50+$20.2KABBV
8$50,795$8,596.74$19,236$210.97+$31.6KABBV
9$71,034$14,549.41$20,796$213.31+$50.2KABBV
10$104,715$25,725.73$22,468$215.52+$82.2KABBV

ABBV vs NOW: Complete Analysis 2026

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →

NOWStock

ServiceNow, Inc. provides enterprise cloud computing solutions that defines, structures, consolidates, manages, and automates services for enterprises worldwide. It operates the Now platform for workflow automation, artificial intelligence, machine learning, robotic process automation, performance analytics, electronic service catalogs and portals, configuration management systems, data benchmarking, encryption, and collaboration and development tools. The company also provides information technology (IT) service management applications; IT service management product suite for enterprise's employees, customers, and partners; IT business management product suite; IT operations management product that connects a customer's physical and cloud-based IT infrastructure; IT Asset Management to automate IT asset lifecycles; and security operations that connects with internal and third party. In addition, it offers governance, risk, and compliance product to manage risk and resilience; human resources, legal, and workplace service delivery products; safe workplace applications; customer service management product; and field service management applications. Further, it provides App Engine product; IntegrationHub enables application to extend workflows; and professional, industry solutions, and customer support services. It serves government, financial services, healthcare, telecommunications, manufacturing, IT services, technology, oil and gas, education, and consumer products through direct sales team and resale partners. It has a strategic partnership with Celonis to help customers identify and prioritize processes that are suitable for automation. The company was formerly known as Service-now.com and changed its name to ServiceNow, Inc. in May 2012. The company was founded in 2004 and is headquartered in Santa Clara, California.

Full NOW Calculator →
📬

Get this ABBV vs NOW comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABBV vs JNJABBV vs MRKABBV vs PFEABBV vs BMYABBV vs LLYABBV vs SCHDABBV vs JEPIABBV vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.